- Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights, and will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications
- NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using its proprietary MATCH™ technology platform
- Novo Holdings co-led Numab’s $110 million Series C financing in 2021 and participated in the Series C extension in 2022
- Michael Bauer, Partner, Venture Investments, Novo Holdings continues on the Board of Numab Therapeutics AG
Read more…
